News on immunoassay systems and applications.
Avacta said it is aiming to complete development of Affimer reagents for the COVID-19 test by the end of May.
MBio is developing the system for use with human host-response biomarker assays that can be used to identify gravely ill or highly contagious individuals.
If the rapid test receives an FDA EUA, it will enable in-home self-testing by patients and medical professionals, the firm said.
The point-of-care test kit, intended for professional use, delivers clinical results within 10 minutes, Beroni said.
The company's approach relies on an initial point-of-care lateral flow assay followed by a confirmatory real-time PCR analysis run in its laboratories.
